Delta-like protein 4/DLL4 Protein, Human (HEK293)

Customer Review

Based on 1 Customer Validation

Delta-like protein 4 (DLL4) functions as a Notch ligand and activates NOTCH1 and NOTCH4 in the Notch signaling pathway. It regulates angiogenesis by inhibiting endothelial cell proliferation, migration, and angiogenesis. Delta-like protein 4/DLL4 Protein, Human (HEK293) is the recombinant human-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with tag free.

For research use only. We do not sell to patients.
  • Species: Human
  • Source: HEK293
  • Storage:
    Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
  • Biological Activity
  • Technical Parameters
  • Product Properties
  • Documentation
  • Help & FAQs

Biological Activity

Description

Delta-like protein 4 (DLL4) functions as a Notch ligand and activates NOTCH1 and NOTCH4 in the Notch signaling pathway. It regulates angiogenesis by inhibiting endothelial cell proliferation, migration, and angiogenesis. Delta-like protein 4/DLL4 Protein, Human (HEK293) is the recombinant human-derived Delta-like protein 4/DLL4 protein, expressed by HEK293 , with tag free.

Background

Delta-like protein 4 (DLL4) is a key participant in the Notch signaling pathway, acting as a Notch ligand with functional implications. It specifically activates NOTCH1 and NOTCH4, contributing to the intricate cellular communication within this signaling cascade. Beyond its role in Notch signaling, DLL4 emerges as a crucial regulator of angiogenesis, exerting a negative influence on endothelial cell proliferation, migration, and angiogenic sprouting. The protein's indispensability extends to retinal progenitor proliferation, where it plays a vital role in suppressing rod fates in late retinal progenitors and ensuring the proper generation of diverse retinal cell types. Additionally, during spinal cord neurogenesis, DLL4 inhibits V2a interneuron fate, adding another layer to its multifaceted functions. The molecular interactions involving DLL4 include its engagement with NOTCH4 and NOTCH1, facilitated by specific domains in DLL4 and NOTCH1, respectively.

Verified Bioactivity

Immobilized Human DLL4 at 0.5 μg/mL (100 μL/well) on the plate. Dose response curve for Anti-DLL4 Antibody with the EC50 of < 10 ng/mL determined by ELISA.

MCE Validation Data

  • Purity - SDS-PAGE

    Purity - SDS-PAGE

    ≥ 95%, as determined by reducing SDS-PAGE.

  • Bioactivity - ELISA

    Bioactivity - ELISA

    Immobilized Recombinant Human DLL4 Protein at 0.5 μg/mL can bind Anti-DLL4 Antibody. The ED50 for this effect is 2.447 ng/mL.

Technical Parameters

  • Species Human
  • Source HEK293
  • Tag Tag Free
  • Accession
  • Gene ID
  • Molecular Construction
    • N-term
    • DLL4 (S27-P524)
      Accession # Q9NR61
    • C-term
  • Protein Length

    Partial Extracellular Domain

  • Synonyms

    DLL4; Notch Ligand Delta-2; Delta Like Canonical Notch Ligand 4; Delta-Like Ligand 4; Drosophila Delta Homolog 4; Delta-Like Protein; Delta-Like Protein 4; Notch Ligand DLL4; Delta4; Delta Ligand 4; Delta-Like 4 Homolog (Drosophila); Hdelta2; Delta-Like 4 (Drosophila); Delta 4; Delta-Like 4 Homolog; AOS6; Delta-Like 4 Protein

  • AA Sequence

    SGVFQLQLQEFINERGVLASGRPCEPGCRTFFRVCLKHFQAVVSPGPCTFGTVSTPVLGTNSFAVRDDSSGGGRNPLQLPFNFTWPGTFSLIIEAWHAPGDDLRPEALPPDALISKIAIQGSLAVGQNWLLDEQTSTLTRLRYSYRVICSDNYYGDNCSRLCKKRNDHFGHYVCQPDGNLSCLPGWTGEYCQQPICLSGCHEQNGYCSKPAECLCRPGWQGRLCNECIPHNGCRHGTCSTPWQCTCDEGWGGLFCDQDLNYCTHHSPCKNGATCSNSGQRSYTCTCRPGYTGVDCELELSECDSNPCRNGGSCKDQEDGYHCLCPPGYYGLHCEHSTLSCADSPCFNGGSCRERNQGANYACECPPNFTGSNCEKKVDRCTSNPCANGGQCLNRGPSRMCRCRPGFTGTYCELHVSDCARNPCAHGGTCHDLENGLMCTCPAGFSGRRCEVRTSIDACASSPCFNRATCYTDLSTDTFVCNCPYGFVGSRCEFPVGLP

  • Predicted Molecular Mass

    54.3 kDa

  • Molecular Weight

    Approximately 55-73 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.

  • Glycosylation

    Yes

  • Purity

    ≥ 95%, as determined by reducing SDS-PAGE.

Product Properties

Appearance

Lyophilized powder

Formulation

1.Lyophilized from a 0.22 μm filtered solution of PBS, 200 mM Arginine, pH 7.4, 8% trehalose.
2.Lyophilized from a 0.22 μm filtered solution of PBS, 200 mM Arginine, pH 7.4.
3.Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 200 mM arginine, 0.2 mM PMSF.
Please refer to the lot-specific COA for specific buffer information.

Endotoxin Level

<1 EU/μg, determined by LAL method.

Reconstitution

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Storage & Stability

Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Shipping

Room temperature in continental US; may vary elsewhere.

Calculators

Reconstitution Calculator

Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration

Volume (to add to vial) Volume (to add to vial)
=
Mass (in vial) Mass (in vial)
÷
Desired Reconstitution Concentration Desired Reconstitution Concentration
Dilution Calculator

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

Concentration (start) Concentration (start)
×
Volume (start) Volume (start)
=
Concentration (final) Concentration (final)
×
Volume (final) Volume (final)
The Specific Activity Calculator Equation
  • Specific Activity (Unit/mg)
  • Biological Activity (ED50)

Specific Activity (Unit/mg) = 106 ÷ Biological Activity (ED50)

Specific Activity (Unit/mg) Specific Activity (Unit/mg)
Unit/mg
= 106 ÷
Biological Activity (ED50) Biological Activity (ED50)
106 ÷
ng/mL
MOQ
Minimum order quantity
100 mg

Get Quote In-stock

Other size
Get Quote
Please select quantity
Amount: USD 0.00